Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...
The Pharma Letter7 天
Fondazione Telethon submits BLA for etuvetidigene autotemcel
Italian biomedical charity Fondazione Telethon, which is focused on rare genetic diseases, revealed it has submitted a ...
The Scientist8 天
A Tale of How TALENs Launched the Genome Editing Revolution
Shortly after this publication, Bogdanove struck up a collaboration with Daniel Voytas, a plant geneticist at the University ...
NHS England21 天
Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 ...
Etanercept and adalimumab are both recommended to be available as routine commissioning treatment options for deficiency of adenosine deaminase type 2 (DADA2) within the criteria set out in these ...
The EMBO Journal22 天
Cytosolic CRISPR RNAs for efficient application of RNA-targeting CRISPR-Cas systems
This month's cover highlights the article Immune cells adapt to confined environments in vivo to optimise nuclear plasticity for migration by Helen Weavers and Tua Karling. The cover features confocal ...